Herein, we conducted this retrospective study to evaluate the efficacy, safety, and potential predictive biomarkers of FOLFOX-HAIC in combination with lenvatinib and PD-1 inhibitor for advanced iCCA. The gene discussed is PDCD1; the disease is infantile convulsions and choreoathetosis.